Studio di fase 3 sul trattamento aggiuntivo con seltorexant in partecipanti adulti e anziani con disturbo depressivo maggiore e sintomi di insonnia
Uno studio multicentrico in due parti, in doppio cieco, randomizzato, controllato con placebo per valutare l'efficacia, la sicurezza e il mantenimento dell'effetto di 20 (milligrammi) mg di Seltorexant come terapia aggiuntiva agli antidepressivi in pazienti adulti e anziani con disturbo depressivo maggiore con sintomi di insonnia
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Buenos Aires, Argentina, C1133AAH
- Attivo, non reclutante
- Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
-
Córdoba, Argentina, 5000FJF
- Attivo, non reclutante
- CEN Consultorios Especializados en Neurociencias
-
Córdoba, Argentina, X5003DCE
- Attivo, non reclutante
- Instituto Medico DAMIC
-
Córdoba, Argentina, X5006CBI
- Attivo, non reclutante
- Centro Medico Luquez
-
Córdoba, Argentina, X5009BIN
- Attivo, non reclutante
- Sanatorio Prof Leon S Morra S A
-
La Plata, Argentina, 1900
- Attivo, non reclutante
- INSA Instituto de Neurociencias San Agustín
-
Rosario, Argentina, 2000
- Attivo, non reclutante
- C I A P Centro de investigacion y Asistencia en Psiquiatria
-
Santiago del Estero, Argentina, 4200
- Attivo, non reclutante
- Clinica El Jardin
-
-
-
-
-
Brasília, Brasile, 70200 730
- Completato
- L2IP Instituto de Pesquisas Clinicas
-
Campinas, Brasile, 13087 567
- Attivo, non reclutante
- CAEP Centro Avancado De Estudos E Pesquisas
-
Criciúma, Brasile, 88811 000
- Attivo, non reclutante
- Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
-
Natal, Brasile, 59012 300
- Completato
- Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
-
Passo Fundo, Brasile, 99010 120
- Sospeso
- Instituto Mederi de Pesquisa e Saude
-
Porto Alegre, Brasile, 90619900
- Completato
- Uniao Brasileira de Educacao e Assistencia INSCER Instituto do Cerebro do Rio Grande do Sul
-
Porto Alegre, Brasile, 90035 903
- Completato
- Hospital De Clinicas De Porto Alegre
-
Porto Alegre, Brasile, 90430001
- Attivo, non reclutante
- NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
-
Rio de Janeiro, Brasile, 22270 060
- Attivo, non reclutante
- Ruschel Medicina e Pesquisa Clínica Ltda
-
São Bernardo do Campo, Brasile, 09726 150
- Attivo, non reclutante
- Centro Integrado Facili
-
São Paulo, Brasile, 01228 000
- Attivo, non reclutante
- CPQuali Pesquisa Clinica LTDA ME
-
São Paulo, Brasile, 01236030
- Attivo, non reclutante
- BR Trials
-
-
-
-
-
Burgas, Bulgaria, 8001
- Attivo, non reclutante
- Mental Health Center Prof. Dr. Ivan Temkov
-
Plovdiv, Bulgaria, 4002
- Attivo, non reclutante
- UMHAT 'Sveti Georgi'- Plovdiv, Psychiatry Clinic
-
Sofia, Bulgaria, 1377
- Completato
- Centre for Mental Health Prof.N.Shipkovenski EOOD
-
Sofia, Bulgaria, 1113
- Attivo, non reclutante
- Medical Center St. Naum
-
Sofia, Bulgaria, 1408
- Attivo, non reclutante
- DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
-
Stara Zagora, Bulgaria, 6010
- Completato
- Medical Center ZaraMed
-
Varna, Bulgaria, 9020
- Attivo, non reclutante
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Brno, Cechia, 61300
- Reclutamento
- Medipa S R O
-
Pilsen, Cechia, 301 00
- Completato
- A Shine S R O
-
Prague, Cechia, 10000
- Reclutamento
- Clintrial s r o
-
Prague, Cechia, 110 00
- Reclutamento
- Neuropsychiatrie Petrska sro
-
Prague, Cechia, 16000
- Reclutamento
- Medical Services Prague S R O
-
Prague, Cechia, 12000
- Completato
- Pragtis S R O
-
-
-
-
-
Barranquilla, Colombia, 080002
- Attivo, non reclutante
- Centro de Investigaciones y Proyectos en Neurociencias CIPNA
-
Bello, Colombia, 051053
- Attivo, non reclutante
- HOMO - ESE Hospital Mental de Antioquia
-
Bogotá, Colombia, 111166
- Completato
- Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
-
Pereira, Colombia, 660001
- Attivo, non reclutante
- Psynapsis Salud Mental S.A.
-
-
-
-
-
Brescia, Italia, 25123
- Completato
- Territorial Social Health Authority of the Spedali Civili of Brescia
-
Catania, Italia, 95123
- Attivo, non reclutante
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Chieti, Italia, 66100
- Attivo, non reclutante
- Universita D Annunzio
-
Genova, Italia, 16132
- Completato
- IRCCS Aor San Martino IST
-
Monza, Italia, 20900
- Completato
- Fondazione IRCCS San Gerardo dei Tintori
-
Pisa, Italia, 56126
- Completato
- Azienda Ospedaliero Universitaria Pisana
-
Roma, Italia, 00168
- Completato
- Policlinico Universitario Agostino Gemelli
-
Roma, Italia, 00189
- Attivo, non reclutante
- Azienda Ospedaliera Sant Andrea
-
Salerno, Italia, 84020
- Completato
- Ospedale S Francesco d Assisi
-
Siena, Italia, 53100
- Attivo, non reclutante
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
-
-
-
-
Mexico City, Messico, 04100
- Reclutamento
- Ketamine Mexico S de RL de C V
-
Mexico City, Messico, 07000
- Reclutamento
- Gabipros SC
-
Mexico City, Messico, 03100
- Completato
- Health Pharma Professional Research
-
Monterrey, Messico, 64710
- Reclutamento
- Instituto de Informacion e Investigacion en Salud Mental A.C.
-
Nuevo León, Messico, 64460
- Reclutamento
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Nuevo León, Messico, 64620
- Completato
- Centro de Estudios Clinicos y Especialidades Medicas S C
-
San Luis de Potosi, Messico, 78218
- Reclutamento
- Hospital Lomas de San Luis Internacional
-
-
-
-
-
Bydgoszcz, Polonia, 85-133
- Reclutamento
- PROMENTE Sp. z o.o.
-
Bydgoszcz, Polonia, 85 794
- Reclutamento
- Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
-
Bydgoszcz, Polonia, 85 605
- Completato
- Centrum Medyczne Intercor Sp z o o
-
Gdansk, Polonia, 80 283
- Reclutamento
- Centrum Zdrowia Alcea
-
Gorlice, Polonia, 30073
- Completato
- Specjalistyczna Praktyka Lekarska Piotr Zalitacz
-
Grudziądz, Polonia, 86 300
- Reclutamento
- Przychodnie Grudziadz sp. z o.o.
-
Katowice, Polonia, 40 514
- Reclutamento
- Clinic BBP Sp z o o
-
Leszno, Polonia, 64-100
- Reclutamento
- Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
-
Poznan, Polonia, 60 192
- Reclutamento
- Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka
-
Warsaw, Polonia, 00-774
- Reclutamento
- Szpital Nowowiejski Osrodek Badan Klinicznych
-
Warsaw, Polonia, 02-172
- Completato
- MTZ Clinical Research Powered by Pratia
-
-
-
-
-
Braga, Portogallo, 4710 243
- Completato
- Uls Braga - Hosp. Braga
-
Leiria, Portogallo, 2410 197
- Completato
- Uls Regiao Leiria - Hosp. Santo Andre
-
Lisbon, Portogallo, 1649 035
- Completato
- Uls Santa Maria - Hosp. Santa Maria
-
Lisbon, Portogallo, 1349 019
- Completato
- Uls Lisboa Ocidental - Hosp. Egas Moniz
-
Lisbon, Portogallo, 1400 038
- Attivo, non reclutante
- Fund. Champalimaud
-
Loures, Portogallo, 2674 514
- Attivo, non reclutante
- Uls Loures Odivelas - Hosp. Loures
-
Ponta Delgada, Portogallo, 9500 370
- Completato
- Hosp. Divino Espirito Santo Ponta Delgada
-
Porto, Portogallo, 4100 180
- Attivo, non reclutante
- Hosp. Cuf Porto
-
Touguinho, Portogallo, 4480-565
- Completato
- Hosp. Central Trofa Saude
-
-
-
-
-
Bucharest, Romania, 041914
- Reclutamento
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
-
Bucharest, Romania, 041914
- Completato
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia 2
-
Cluj-Napoca, Romania, 400012
- Completato
- Spitalul Clinic Judetean de Urgenta Cluj Napoca
-
Cluj-Napoca, Romania, 400012
- Completato
- Spitalul Clinic Judetean de Urgenta Cluj Napoca 1
-
Craiova, Romania, 200157
- Reclutamento
- Centrul Medical Melchisedec
-
Focşani, Romania, 620117
- Completato
- CMI Dr. Sarpe Marcel-Claudiu
-
Iași, Romania, 700282
- Completato
- Institutului Regional de Psihiatrie 'Socola' Iasi
-
Iași, Romania, 700282
- Completato
- Institutului Regional de Psihiatrie Socola Iasi 1
-
Iași, Romania, 700282
- Completato
- Institutului Regional de Psihiatrie Socola Iasi 2
-
Oradea, Romania, 410169
- Reclutamento
- Spitalul Clinic Judetean de Urgenta Oradea
-
Sibiu, Romania, 550082
- Completato
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
-
Sibiu, Romania, 550082
- Completato
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda 1
-
Sânpetru, Romania, 507190
- Reclutamento
- Spitalul de Psihiatrie si Neurologie Brasov
-
-
-
-
-
Belgrade, Serbia, 11000
- Attivo, non reclutante
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Attivo, non reclutante
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Gornja Toponica, Serbia, 18202
- Attivo, non reclutante
- Special Hospital for Psychiatric Diseases Gornja Toponica
-
Kovin, Serbia, 26220
- Completato
- Special Hospital for Psychiatric Diseases Kovin
-
Novi Kneževac, Serbia, 23330
- Completato
- Specialized Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Bratislava, Slovacchia, 821 01
- Completato
- Psychiatricka Ambulancia Mentum S.R.O.
-
Košice, Slovacchia, 040 01
- Reclutamento
- Univerzitna nemocnica L. Pasteura Kosice
-
Liptovský Mikuláš, Slovacchia, 031 23
- Reclutamento
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Slovacchia, 979 01
- Reclutamento
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Svidník, Slovacchia, 089 01
- Reclutamento
- Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.
-
Vranov nad Topľou, Slovacchia, 093 01
- Reclutamento
- Crystal Comfort s.r.o.
-
-
-
-
-
Barcelona, Spagna, 08036
- Attivo, non reclutante
- Hosp Clinic de Barcelona
-
Barcelona, Spagna, 8035
- Completato
- Hosp Univ Vall D Hebron
-
Barcelona, Spagna, 08025
- Attivo, non reclutante
- Institucion Hosp Hestia Palau
-
Bilbao, Spagna, 48013
- Completato
- Hosp. Univ. de Basurto
-
Collado Villalba, Spagna, 28400
- Completato
- Hosp. Gral. de Villalba
-
Madrid, Spagna, 28034
- Completato
- Hospital Ramon y Cajal
-
Madrid, Spagna, 28031
- Attivo, non reclutante
- Hosp. Univ. Infanta Leonor
-
Madrid, Spagna, 28046
- Attivo, non reclutante
- Hosp. Univ. La Paz
-
Torrevieja, Spagna, 03186
- Completato
- Hosp. Univ. de Torrevieja
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- Completato
- University of Alabama at Birmingham
-
-
Arizona
-
Chandler, Arizona, Stati Uniti, 85224
- Completato
- Chandler Clinical Trials
-
Tucson, Arizona, Stati Uniti, 85724
- Reclutamento
- University of Arizona
-
-
Arkansas
-
Bryant, Arkansas, Stati Uniti, 72022
- Reclutamento
- SanRo Clinical Research Group LLC WCG Clinical Network
-
Little Rock, Arkansas, Stati Uniti, 72211
- Completato
- Preferred Research Partners
-
-
California
-
Anaheim, California, Stati Uniti, 92801
- Reclutamento
- PAMOJA Clinical Institute LLC
-
Colton, California, Stati Uniti, 92324
- Reclutamento
- Axiom Research
-
Encino, California, Stati Uniti, 91316
- Completato
- Elite Research Network 6
-
Glendale, California, Stati Uniti, 91206
- Reclutamento
- Behavioral Research Specialists LLC
-
Los Alamitos, California, Stati Uniti, 90720
- Completato
- WR PRI Los Alamitos
-
Oceanside, California, Stati Uniti, 92056
- Reclutamento
- Excell Research Inc
-
Rancho Cucamonga, California, Stati Uniti, 91730
- Completato
- Prospective Research Innovations Inc
-
Redlands, California, Stati Uniti, 92374
- Reclutamento
- Anderson Clinical Research
-
San Jose, California, Stati Uniti, 95124
- Reclutamento
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Stati Uniti, 92705
- Completato
- Syrentis Clinical Research
-
Sherman Oaks, California, Stati Uniti, 91403
- Completato
- California Neuroscience Research
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80209
- Reclutamento
- Mountain View Clinical Research
-
-
Connecticut
-
Farmington, Connecticut, Stati Uniti, 06030
- Reclutamento
- UConn Health Center
-
-
Florida
-
Brandon, Florida, Stati Uniti, 33511
- Reclutamento
- Clinical Research of Brandon
-
Hialeah, Florida, Stati Uniti, 33012
- Attivo, non reclutante
- AGA Clinical Trials
-
Hialeah, Florida, Stati Uniti, 33012
- Attivo, non reclutante
- Reliable Clinical Research
-
Homestead, Florida, Stati Uniti, 33033
- Attivo, non reclutante
- Advanced Research Institute of Miami
-
Jacksonville, Florida, Stati Uniti, 32256
- Attivo, non reclutante
- Clinical NeuroScience Solutions Inc
-
Lake City, Florida, Stati Uniti, 32055
- Completato
- Multi Specialty Research Associates Inc
-
Largo, Florida, Stati Uniti, 33777
- Completato
- Alcanza Clinical Research
-
Miami, Florida, Stati Uniti, 33186
- Reclutamento
- Nuovida Research Center
-
Miami, Florida, Stati Uniti, 33126
- Attivo, non reclutante
- Pharmax Research Clinic Inc
-
Miami, Florida, Stati Uniti, 33176
- Attivo, non reclutante
- Miami Dade Medical Research Institute
-
Naples, Florida, Stati Uniti, 34105
- Completato
- Aqualane Clinical Research
-
North Bay Village, Florida, Stati Uniti, 33141
- Completato
- Bravo Health Care Center
-
Orlando, Florida, Stati Uniti, 32803
- Attivo, non reclutante
- Nova Psychiatry INC
-
Saint Augustine, Florida, Stati Uniti, 32086
- Completato
- Florida Center for TMS
-
Tampa, Florida, Stati Uniti, 33613
- Completato
- University of South Florida
-
Tampa, Florida, Stati Uniti, 33629
- Reclutamento
- Interventional Psychiatry of Tampa Bay
-
Tampa, Florida, Stati Uniti, 33614
- Reclutamento
- Psych Me Medical Research Inc
-
West Palm Beach, Florida, Stati Uniti, 33407
- Reclutamento
- Health Synergy Clinical Research
-
Winter Park, Florida, Stati Uniti, 32789
- Completato
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30328
- Reclutamento
- Agile Clinical Research Trials, LLC
-
Atlanta, Georgia, Stati Uniti, 30318
- Attivo, non reclutante
- Advanced Discovery Research
-
Decatur, Georgia, Stati Uniti, 30030
- Attivo, non reclutante
- iResearch Atlanta LLC
-
Dunwoody, Georgia, Stati Uniti, 30338
- Completato
- Peachford Hospital-Atlanta Behavorial Research
-
Savannah, Georgia, Stati Uniti, 31405
- Completato
- iResearch Savannah
-
Snellville, Georgia, Stati Uniti, 30078
- Completato
- Renew Health Clinical Research
-
Snellville, Georgia, Stati Uniti, 30078
- Completato
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60614
- Completato
- MetroMed Clinical Research
-
Chicago, Illinois, Stati Uniti, 60637
- Completato
- University of Chicago Medical Center
-
Elgin, Illinois, Stati Uniti, 60123
- Completato
- Revive Research Institute
-
Naperville, Illinois, Stati Uniti, 60563
- Reclutamento
- Baber Research Group
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02131
- Completato
- Boston Clinical Trials
-
Watertown, Massachusetts, Stati Uniti, 02472
- Reclutamento
- Adams Clinical LLC
-
-
Minnesota
-
Mankato, Minnesota, Stati Uniti, 56001
- Completato
- Mankato Clinic
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89121
- Completato
- Oasis Clinical Research LLC
-
Las Vegas, Nevada, Stati Uniti, 89119
- Completato
- Redbird Research
-
-
New Hampshire
-
Portsmouth, New Hampshire, Stati Uniti, 03801
- Completato
- ActivMed Practices and Research
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11235
- Reclutamento
- SPRI Clinical Trials, LLC
-
Brooklyn, New York, Stati Uniti, 11229
- Reclutamento
- Integrative Clinical Trials LLC
-
Buffalo, New York, Stati Uniti, 14202
- Completato
- University at Buffalo Psychiatry
-
Mount Kisco, New York, Stati Uniti, 10549
- Reclutamento
- Bioscience Research LLC
-
New York, New York, Stati Uniti, 10017
- Reclutamento
- Fieve Clinical Research Inc
-
New York, New York, Stati Uniti, 10022
- Completato
- Hapworth Psychiatric Medical PLLC
-
Woodbury, New York, Stati Uniti, 11797
- Completato
- Lucian Miron Manu MD Psychiatry PC
-
-
North Carolina
-
Hickory, North Carolina, Stati Uniti, 28601
- Completato
- IMA Clinical Research PC 3
-
-
Ohio
-
Avon Lake, Ohio, Stati Uniti, 44012
- Completato
- Haidar Almhana Nieding
-
Cincinnati, Ohio, Stati Uniti, 45215
- Reclutamento
- Patient Priority Clinical Sites LLC
-
Cincinnati, Ohio, Stati Uniti, 45219
- Completato
- University of Cincinnati College of Medicine
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University
-
Middleburg Heights, Ohio, Stati Uniti, 44130
- Completato
- North Star Medical Research
-
-
Oklahoma
-
Edmond, Oklahoma, Stati Uniti, 73013
- Reclutamento
- Conrad Clinical Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Completato
- Medical University of South Carolina
-
Charleston, South Carolina, Stati Uniti, 29406
- Reclutamento
- Clinical Trials of South Carolina
-
-
Texas
-
Austin, Texas, Stati Uniti, 78712
- Completato
- The University of Texas at Austin
-
Austin, Texas, Stati Uniti, 78759
- Completato
- BioBehavioral Research of Austin PC
-
Bellaire, Texas, Stati Uniti, 77401
- Reclutamento
- Houston Clinical Trials LLC
-
Dallas, Texas, Stati Uniti, 75243
- Completato
- Relaro Medical Trials
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- North Texas Clinical Trials
-
Garland, Texas, Stati Uniti, 75041
- Completato
- VAST Clinical Research
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine
-
Houston, Texas, Stati Uniti, 77081
- Completato
- DM Clinical Research
-
Stafford, Texas, Stati Uniti, 77477
- Attivo, non reclutante
- R and H Clinical Research
-
Wichita Falls, Texas, Stati Uniti, 76309
- Reclutamento
- Grayline Research Center
-
-
Utah
-
Draper, Utah, Stati Uniti, 84020
- Completato
- Cedar Clinical Research
-
-
Washington
-
Everett, Washington, Stati Uniti, 98201
- Reclutamento
- Core Clinical Research
-
-
-
-
-
Lund, Svezia, 22222
- Reclutamento
- ProbarE i Lund AB
-
Mölndal, Svezia, 43153
- Reclutamento
- CTC GoCo
-
Stockholm, Svezia, 114 37
- Reclutamento
- ProbarE i Stockholm AB
-
Uppsala, Svezia, 75237
- Reclutamento
- CTC MTC Uppsala
-
-
-
-
-
Ankara, Turchia (Türkiye), 06010
- Reclutamento
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara, Turchia (Türkiye), 06800
- Completato
- Ankara Bilkent Sehir Hastanesi
-
Ankara, Turchia (Türkiye), 06620
- Completato
- Ankara University Medical Faculty
-
Bursa, Turchia (Türkiye), 16285
- Completato
- Bursa High Speciality Training and Research Dortcelik Mental Hospital
-
Bursa, Turchia (Türkiye), 16059
- Completato
- Uludag Universitesi Tıp Fakultesi Hastanesi
-
Gaziantep, Turchia (Türkiye), 27580
- Reclutamento
- Gaziantep Universitesi Tip Fakultesi
-
Istanbul, Turchia (Türkiye), 34736
- Completato
- Erenkoy Mental Hospital
-
Kocaeli, Turchia (Türkiye), 41001
- Reclutamento
- Kocaeli University Medical Faculty
-
Samsun, Turchia (Türkiye), 55020
- Reclutamento
- Liv Hospital
-
Trabzon, Turchia (Türkiye), 61080
- Completato
- Karadeniz Teknik University Medical Faculty
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Participants in part 1 and direct enrollers to part 2:
- Meet DSM-5 MDD, without psychotic features based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. An inadequate response is defined as less than (<) 50% reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ, and this must include the participant's current antidepressant treatment
- Is receiving and tolerating well any one of the following SSRI or SNRI for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks
- Having a major depressive episode of at least moderate severity, as assessed with 17-item Hamilton Depression Rating Scale, implemented through the Structured Interview Guide (SIGH-D) in a blinded manner at screening and must not demonstrate a clinically significant improvement from the beginning to end of screening.
Participants entering after completing part 1:
- Must have completed Part 1 DB treatment phase
- Can consistently tolerate study drug (at the end of Part 1), and there is no additional safety risk for the participant if they proceed to Part 2
- Was able to consistently follow the study procedures in Part 1 as judged by the investigator.
- Must be medically stable based on clinical laboratory tests
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of narcolepsy and seizures
- Has current signs/symptoms of hypothyroidism or hyperthyroidism
- Participants taking thyroid supplementation for antidepressant purposes
- Has Cushing's disease, Addison's disease, primary amenorrhea, or other evidence of significant medical disorders of the HPA axis
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: Seltorexant
Participants will receive seltorexant orally once daily for 6 weeks during the double-blind (DB) treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant throughout the study. |
Seltorexant will be administered orally.
Altri nomi:
SSRI/SNRI will be administered orally. |
|
Comparatore placebo: Part 1: Placebo
Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
|
Sperimentale: Part 2: Open Label (OL) Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. In Part 2 open-label phases (induction and stabilization) all participants (newly enrolled direct entry participants and Part 1 roll-over participants) will receive seltorexant orally in addition to their background SSRI/SNRI treatment. |
Seltorexant will be administered orally.
Altri nomi:
SSRI/SNRI will be administered orally. |
|
Sperimentale: Part 2: DB Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phase will receive treatment with seltorexant orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
Seltorexant will be administered orally.
Altri nomi:
SSRI/SNRI will be administered orally. |
|
Comparatore placebo: Part 2: DB Placebo
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phases will receive treatment with matching placebo orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43
Lasso di tempo: Baseline, Day 43
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Response
Lasso di tempo: Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable response is defined as a greater than equal to (>=) 50 percent (%) reduction in the MADRS total score for the last 3 consecutive visits of the OL stabilization Phase, as assessed by the site investigator. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve a stable response at the end of OL seltorexant treatment will be reported. |
Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score at Day 43
Lasso di tempo: Baseline, Day 43
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score at Day 43
Lasso di tempo: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in the MADRS-6 Total Score at Day 43
Lasso di tempo: Baseline, Day 43
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of major depressive disorder (MDD) symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
Baseline, Day 43
|
|
Part 1: Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total score From Baseline to Day 43
Lasso di tempo: From Baseline to Day 43
|
Responders are defined as participants with >= 50 percent improvement in the MADRS total score from baseline to Day 43. |
From Baseline to Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (4a) T-score at Day 43
Lasso di tempo: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Lasso di tempo: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score at Day 43
Lasso di tempo: Baseline, Day 43
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Remission
Lasso di tempo: Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable remission is defined as MADRS total score less than or equal to (<=)10 and CGI-S <= 2 for at least 4 consecutive weeks of the OL stabilization Phase. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve stable remission at the end of the OL seltorexant treatment will be reported. |
Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (8a) T-Score
Lasso di tempo: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (4a) T-Score
Lasso di tempo: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Lasso di tempo: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in MADRS Total Score
Lasso di tempo: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of DB Maintenance Phase in PHQ-9 Score
Lasso di tempo: From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
|
Change From Baseline to Endpoint of the DB Maintenance Phase in the MADRS-6 score
Lasso di tempo: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Change from Baseline to Endpoint of the DB Maintenance Phase in the MADRS symptoms other than insomnia MADRS Without Sleep Item (MADRS-WOSI)
Lasso di tempo: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trail, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Disturbi dell'umore
- Disordine depressivo
- Disturbo depressivo, maggiore
- Effetti fisiologici dei farmaci
- Meccanismi molecolari dell'azione farmacologica
- Agenti neurotrasmettitori
- Modulatori del trasporto a membrana
- Inibitori dell'assorbimento dei neurotrasmettitori
- Agenti della serotonina
- Azioni farmacologiche
- Azioni e usi chimici
- Inibitori selettivi della ricaptazione della serotonina
- Seltorexant
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 42847922MDD3003
- 42847922MDD3003 (Altro identificatore: Janssen Research & Development, LLC)
- 2023-509070-36-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www janssen, com/clinical-trialsitransparency. As noted on this site, requests for access to the study data can be submitted through 'Yale Open Data Access (YODA) Project site at yoda yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .